Transcription therapy for acute promyelocytic leukaemia

Bibliography

• LEWIS B: In: Genes. Oxford University Press, Oxford, UK (1994):879. LOOK T: Oncogenic transcription factors in human leukemias. Science (1994) 278:1059-1064. CALABRETTA B, SKORSKI T, RATAJCZAK MZ, GEWIRTZ AM: Antisense strategies in the treatment of leukemias. Sem. Oncol. (1996) 23:78–87.
   Google Scholar
• PACE U, BOCKMAN JM, MACKAY BJ, MILLER WH JR, DMITROVSKY E, GOLDBERG AR: A ribozyme which discriminates in vitro between PML/RAR alpha, the t(15;17)-associated fusion RNA of acute promyelocytic leukemia, and PM1 and RAR alpha, the transcripts from the nonrearranged alleles. Cancer Res. (1994) 54:6365–6369.
   PubMed Web of Science ®Google Scholar
• GOTTESFELD JM, NEELY L, TRAUGER JW, BAIRD EE, DERVAN PB: Regulation of gene expression by small molecules. Nature (1997) 387:202–205.
   PubMed Web of Science ®Google Scholar
• MELNICK A, LICHT JD: Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood (1999) 93:3167–3215.
   PubMed Web of Science ®Google Scholar
• ••A detailed review of the molecular biology of APLdescribing the different translocations and gene rearrange-ments and the mechanism of leukemogenesis and response to ATRA treatment.
   Google Scholar
• HILLESTAD LK: Acute promyelocytic leukemia. Acta Med. Scand. (1957):189–194.
   PubMed Web of Science ®Google Scholar
• BENNET JM, CATOVSKY D, DANIEL, MT et al.: Proposals for the classification of the acute leukemia. Br. J. Haematol. (1976) 33:451–458.
   PubMed Web of Science ®Google Scholar
• BENNET JM, CATOVSKY D, DANIEL MT et al.: Proposed revised criteria for the classification of acute myeloid leukemia. Ann. Inter. Med. (1985) 103:620–625.
   PubMed Web of Science ®Google Scholar
• BENNET JM, CATOVSKY D, DANIEL MT et al.: A variantform of hypogranular promyelocytic leukemia (M3). Br. J. Hematol. (1980) 44:169–178.
   PubMedGoogle Scholar
• ROWLEY JD, GOLOMB HM, DOUGHERTY C: 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia [letter]. Lancet (1977) 1:549–550.
   PubMed Web of Science ®Google Scholar
• CASSILETH PA, LYNCH E, HINES JD et al.: Varyingintensity of postremission therapy in acute myeloid leukemia. Blood (1992) 79:1924–1930.
   PubMed Web of Science ®Google Scholar
• MAYER RJ, DAVIS RB, SCHIFFER CA et al.: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl. J. Med. (1994) 331:896–903.
   PubMed Web of Science ®Google Scholar
• HEAD D, KOPECKY KJ, WEICK J et al.: Effect of aggressive daunomycin therapy on survival in acute promyelo-cytic leukemia. Southwest Oncology Group. Blood (1995) 86:1717–1728.
   Google Scholar
• SCHIFFER CA, LEE EJ, TOMIYASU T, WIERNIK PH, TESTAJR: Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood (1989) 73:263–270.
   PubMed Web of Science ®Google Scholar
• ARTHUR DC, BERGER R, GOLOMB HM et al.: The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genet. Cytogenet. (1989) 40:203–216.
   PubMed Web of Science ®Google Scholar
• ARGYLE JC, BENJAMIN DR, LAMPKIN B, HAMMOND D: Acute non-lymphocytic leukemias of childhood: inter-observer variability and problems in the use of the FAB classification. Cancer (1989) 63:295–301.
   PubMed Web of Science ®Google Scholar
• BERGER R, BERNHEIM T, OCHOA-NOGUERA ME et al.: Prognostic significance of chromosomal abnormali-ties in acute nonlymphocytic leukemia: a study of 343 patients. Cancer Genet. Cytogenet.(1987) 28:293–299.
   PubMed Web of Science ®Google Scholar
• FENAUX P, PREUDHOMME C, LAI JL, MOREL P, BEUSCART R, BAUTERS F: Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 case. Br. J. Haematol (1989) 73:61–67.
   PubMed Web of Science ®Google Scholar
• DOUER D, PRESTON-MARTIN S, CHANG E, NICHOLS PW, WATKINS K, LEVINE AM: High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood (1996) 87:308–313.
   PubMed Web of Science ®Google Scholar
• RUIZ-AReELLES GJ: Promyelocytic leukemia in Mexican mestizos. Blood (1997) 89:348–349.
   PubMed Web of Science ®Google Scholar
• OTERO JC, SANTILLANA S, FEREYROS G: High frequency of acute promyelocytic leukemia among latinos with acute myeloid leukemia. Blood (1996) 88:377.
   PubMed Web of Science ®Google Scholar
• DOUER D, COZEN W, WANG F, CHANG E, PRESTON-MARTIN S, LEVINE AM: Descriptive epidemiology of acute promyelocytic leukemia (APL): Report from the Cancer Registry for Los Angeles County, 1972–1995. Blood (1997) 90 (Suppl. 0:310.
   Google Scholar
• STONE RM, MAYER RJ: The unique aspects of acutepromyelocytic leukemia. J. Clin. Oncol. (1990) 8:1913–1921.
   PubMed Web of Science ®Google Scholar
• GRIGNANI F, FAGIOLI M, ALCALAY M et al.: Acutepromyelocytic leukemia: from genetics to treatment. Blood (1994) 83:10–25.
   PubMed Web of Science ®Google Scholar
• GOLOMB HN, ROWELY JD, VARDIMAR JV, TESTA JR, BUTLER A: `Microgranular' acute promyelocytic leukemia: a distinct clinical, ultarstructural and cytogenetic entity. Blood (1980) 55:253–261.
   Google Scholar
• ROVELLI A, BIONDI A, CANTU-RAJNOLDI A et al.:Microgranular variant of acute promyelocytic leukemia (FAB M3v) in children. J. Clin. Oncol. (1992) 10:1413–1421.
   PubMed Web of Science ®Google Scholar
• BERNARD J, WEIL M, BOIRON M, JACQUILLAT C, FLANDRIN G, GEMON MF: Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood (1973) 41:489–496.
   PubMed Web of Science ®Google Scholar
• AVVISATI G, MANDELLI F, PETTI MC et al.: Idarubicin(4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA. Eur. J. Hematol (1990) 44:257–260.
   PubMed Web of Science ®Google Scholar
• BREITMAN TR, SELONIK SE, COLLINS SJ: Induction ofdifferentiation of human progranulocytic leukemia cell line (HL-60) by retinoic acid. Proc. Natl. Acad. Med. (1980) 77:2936–2940.
   PubMed Web of Science ®Google Scholar
• BREITMAN TR, COLLINS SJ, KEENE BR: Terminal differ-entiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood (1981) 57:1000–1004.
   PubMed Web of Science ®Google Scholar
• CHOMIENNE C, BALLERINI P, BALITRAND N et al.:All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood (1990) 76:1710–1717.
   Google Scholar
• HUANG ME, YE YC, CHEN SR et al.: Use ofall-trans-retinoic acid in the treatment of acute promyelocytic leukemia. Blood (1988) 72:567–572.
   PubMed Web of Science ®Google Scholar
• PETKOVICH M, BRAND NJ, KRUST A, CHAMBON P: A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature (1987) 330:444–449.
   PubMed Web of Science ®Google Scholar
• GIGUERE V, ONG ES, SEGUI P, EVANS RM: Identificationof a receptor for the morphogen retinoic acid. Nature (1987) 330:624–629.
   PubMed Web of Science ®Google Scholar
• MATTEI MG, PETKOVICH M, MATTEI JF, BRAND N, CHAMBON P: Mapping of the human retinoic acid receptor to theq21 band of chromosome 17. Human Genet. (1988) 80:186–188.
   PubMed Web of Science ®Google Scholar
• DE THE H. CHOMIENNE C, LANOTTE M, DOGOS L, DEJEAN A: The 015;17) translocation of acutc promye-locytic leukaemia fuses the retinoic acid receptor F128 aF255 gene to a novel transcribed locus. Nature (1990) 347:558–561.
   PubMedGoogle Scholar
• BORROW J, GODDARD AD, SHEER D, SOLOMON E: Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science (1990) 249:1577–1580.
   PubMed Web of Science ®Google Scholar
• KAKIZUKA A, MILLER WH, UMESONO K et al.: Chromo-somal translocation 015;17) in human acute promye-locytic leukemia fuses RAR-F128 aF255 with a novel putative transcription factor, PML. Cell (1991) 66:663–674.
   PubMed Web of Science ®Google Scholar
• ALCALAY M, ZANGWILL D, PANDOLFI PP et al.: Translo-cation breakpoint of acute promyelocytic leukemia lies within retinoic acid receptor a locus. Proc. Nati Acad. ScL USA (1991) 88:1977–1981.
   PubMed Web of Science ®Google Scholar
• DOWNING JR: The AML 1- ETO chimeric transcriptionfactor in acute myeloid leukemia: Biological and clinical significance. Br. J. Haematol. (1999) 106:296–308.
   PubMedGoogle Scholar
• GOLUB TR, BARKER GF, BOHLANDER SK et al.: Fusion ofthe TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl. Acad. ScL USA (1995) 92:4917–4921.
   PubMed Web of Science ®Google Scholar
• LIU P, TARLE SA, HAJRA A et al.: Fusion betweentranscription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science (1993) 261:1041–1044.
   PubMed Web of Science ®Google Scholar
• PANDOLFI PP, GRIGNANI F, ALCALAY M et al.: Structure and origin of the acute promyelocytic leukemia myl/RAR-a cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene (1991) 6:1285.
   PubMed Web of Science ®Google Scholar
• PANDOLFI PP, ALCALAY M, FAGIOLI M et al.: Genomic variability and alternative splicings generate multiple myl/RAR-a transcripts that encode aberrant myl proteins and myl/RAR- a isoforms in acute promyelo-cytic leukemias. EMBO (1992) 11:1397–1408.
   PubMed Web of Science ®Google Scholar
• GRIMWADE D: The pathogenesis of acute promyelo-cytic leukemia: evaluation of the role of molecular diagnosis and monitoring in malignancy of the disease. Br. J. Haematol (1999):591–613.
   PubMed Web of Science ®Google Scholar
• ••A detailed review of the pathogenesis of APL and the use ofmolecular biology techniques to monitor the response to treatment and make clinical decisions.
   Google Scholar
• DONG S, GENG J-P, TONG J-H et al.: Breakpoint clusters of the PML gene in acute promyelocytic leukemia: Primary structure of the reciprocal products of the PML-RAR F128aF255 gene in a patient with 015;17). Genes Chromosomes Cancer (1993) 8:133–145.
   Google Scholar
• BIONDI A, RAMBALDI A, PANDOLFI PP et al.: Molecular monitoring of the myl/retinoic acid receptor- F128 aF255 fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood (1992) 80:492–497.
   PubMed Web of Science ®Google Scholar
• CHANG KS, LU JF, WANG G et al.: The 015;17) breakpoint in acute promyelocytic leukemia clusters within two different sites of the PML gene: targets for the detection of minimal residual disease by polymerase chain reaction. Blood (1992) 79:554–558.
   PubMed Web of Science ®Google Scholar
• GALLAGHER RE, LI YP, RAO S et al.: Characterization ofacute promyelocytic leukemia cases with PML-RARa break/fusion sites in PML exon6: identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid. Blood (1995) 86:1540–1547.
   PubMed Web of Science ®Google Scholar
• GALLAGHER RE, WILLMAN CL, SLACK JL et al.: Associa-tion of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood (1997) 90:1656–1663.
   PubMed Web of Science ®Google Scholar
• FUKUTANI H, NAOE T, OHNO R et al.: Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. Leukemia (1995) 9:1478–1482.
   PubMed Web of Science ®Google Scholar
• KANE JR, HEAD DR, BALAZS L et al.: Molecular analysis of the PML/RARa chimeric gene in pediatric acute promyelocytic leukemia. Leukemia (1996) 10:1296–1301.
   PubMed Web of Science ®Google Scholar
• CHANG E, LEVINE AM, SLOVAK M, FORMAN S, DOUER D: Acute promyelocytic leukemia in Latino patients is associated with a high frequency of the bcrl breakpoint site in the rearranged PML gene. Blood (1996) 88\(Suppl. 1):665a.
   Google Scholar
• CHEN SJ, ZELENT, A, TONG JH et al.: Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from 011;17) (q23;q21) in a patient with acute promyelocytic leukemia. J. Clin. Invest. (1993) 91:2260–2267.
   PubMed Web of Science ®Google Scholar
• REDNER RL, COREY SJ, RUSH EA: Differentiation of05;17) variant acute promyelocytic leukemic blasts by all-trans retinoic acid. Leukemia (1997) 11:1014–1016.
   PubMed Web of Science ®Google Scholar
• WELLS RA, CATZAVELOS C, KAMEL-REID S: Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nature Genet. (1997) 17:109–113.
   PubMed Web of Science ®Google Scholar
• LICHT JD, CHOMIENNE C, GOY A et al.: Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translo-cation (11;17). Blood (1995) 85:1083–1094.
   PubMed Web of Science ®Google Scholar
• HOFFMAN C, EICHELE G: Retinoids in development. In: The Retinoids: Biology, Chemistry and Medicine. 2nd Edition. Sporn MB, Roberts AB, Goodman DS (Eds.) Raven Press, New York (1994):387–442.
   Google Scholar
• MEANS AL, GUDAS LJ: The role of retinoids invertebratedevelopment. Ann. Rev. Biochem. (1995) 64:201–233.
   PubMed Web of Science ®Google Scholar
• MANGELSDORF DJ, UMESONO K, EVANS RM: The retinoid receptors. In: The Retinoids: Biology Chemistry and Medicine 2nd Edition. Sporn MB, Roberts AB, Goodman DS (Eds.) Raven Press, New York, USA (1994):319–350.
   Google Scholar
• MANGELSDORF DJ, EVANS RM: The RIM heterodimers and orphan receptors. Cell (1995) 83:841–850.
   PubMed Web of Science ®Google Scholar
• CHAMBON P: A decade of molecular biology of retinoic acid receptors. FASEB J. (1996) 10:940–954.
   PubMed Web of Science ®Google Scholar
• LABRECQUE J, ALLAN D, CHAMBON P, ISCOVE NN, LOHNES D, HOANG T: Impaired granulocytic differen-tiation in vitro in hematopoietic cells lacking retinoic acid receptors. Blood (1998) 92: 607–615.
   PubMed Web of Science ®Google Scholar
• TSAI S, COLLINS SJ: A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocytic stage. Proc. Natl. Acad. Sci. USA (1993) 90:7153–7157.
   PubMed Web of Science ®Google Scholar
• WEIS K, RAMBAUD S, LAVAU C et al. Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell (1994) 76:345–356.
   PubMed Web of Science ®Google Scholar
• MU ZM, CHIN KV, LIU JH, LOZANO G, CHANG KS: PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol. (1994) 14:6858–6867.
   PubMed Web of Science ®Google Scholar
• GRIGNANI FR, FERRUCI PF, TESTA U et al.: The acute promyelocytic leukemia specific PML/RARa fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell (1993) 74:423–431.
   PubMed Web of Science ®Google Scholar
• GRISOLANO JL, WESSELSCHMIDT RL, PELICCI PG, LEY TJ: Altered myeloid development and acute leukemia in transgenic mice expressing PML-RARa under control of cathespin G regulatory sequences. Blood (1997) 89:376–387.
   PubMed Web of Science ®Google Scholar
• HE LZ, TRIBIOLI C, RIVI R et al.: Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc. Natl. Acad. ScI USA (1997) 94:5302–5307.
   PubMed Web of Science ®Google Scholar
• BROWN D, KOGAN S, LAGASSE E et al: A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc. Natl. Acad. ScL USA (1997) 94:2551–2556.
   PubMed Web of Science ®Google Scholar
• DE THE. H, LAVAU C, MARCHIO A, CHOMIENNE C, DEGOS L, DEJEAN A: The PML/RAR-a fusion mRNA generated by the 015;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell (1991) 66:675–684.
   PubMed Web of Science ®Google Scholar
• PEREZ A, KASTNER P, SETHI S, LUTZ Y, REIBEL C, CHAMBON P: PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with EBMO J. (1993) 12:3171–3188.
   Google Scholar
• VASILY V, OGRYZKO, SCHILTZ R, RUSSANOVA V, HOWARD BH, NAKATANI Y: The transcriptional coacti-vators p300 and CBP are histone acetyltransferases. Cell (1996) 87:953–959.
   PubMed Web of Science ®Google Scholar
• SPENCER TE, JENSTER G, BURCIN MM et al.: Steroid receptor coactivator-1 is a histone acetyltransferase. Nature (1997) 389:194–198.
   PubMed Web of Science ®Google Scholar
• CHEN H, LIN RJ, SCHILTZ RL et al.: Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell (1997) 90:569–580.
   PubMed Web of Science ®Google Scholar
• ROTH SY, ALLIS CD: Histone acetylation and chromatin assembly: A single escort, multiple dances? Cell (1996) 87:5–8.
   PubMed Web of Science ®Google Scholar
• NAGY L, KAO HY, CHAKRAVARTI D et al.: Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell (1997):373–380.
   PubMed Web of Science ®Google Scholar
• CHEN JD, EVANS RM: A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature (1995) 377:454–457.
   PubMed Web of Science ®Google Scholar
• HEINZEL T, LAVINSKY RM, MULLEN TM et al.: A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature (1997) 387:43–48.
   PubMed Web of Science ®Google Scholar
• BOURGUET W, RUFF M, CHAMBON P, GRONEMEYER H,MORAS D: Crystal structure of the ligand-binding domain of the human nuclear receptor IDCR-alpha. Nature (1995) 375:377–382.
   PubMed Web of Science ®Google Scholar
• GRIGNANI F, DE MATTEIS S, NERVI C et al: Fusionproteins of the retinoic acid receptor- recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 391:815–818.
   PubMed Web of Science ®Google Scholar
• HE LZ, GUIDEZ F, TRIBIOLI C etal: Distinct interactionsof PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nature Genet. (1998) 18:126–135.
   PubMed Web of Science ®Google Scholar
• LIN RJ, NAGY L, INOUE S, SHAO W, MILLER WH JR, EVANSRM: Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (1998) 391:811–814.
   PubMed Web of Science ®Google Scholar
• DYCK JA, MAUL GG, MILLER WH JR, CHEN JD, KAKIZUKAA, EVANS RM: A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell (1994) 76:333–343.
   PubMed Web of Science ®Google Scholar
• KOKEN MH, PUVION-DUTILLEUL F, GUILLEMIN MC etal.:The 015;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J. (1994) 13:1073–1083.
   Google Scholar
• GUIDEZ F, WINS S, ZHU J, SODERSTROM M, WAXMAN S,ZELENT A: Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RAR underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood (1998) 91:2634–2642.
   PubMed Web of Science ®Google Scholar
• RAELSON JV, NERVI C, ROSENAUER A et al.: ThePML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood (1996) 88:2826–2832.
   PubMed Web of Science ®Google Scholar
• YOSHIDA H, KITAMURA K, TANAKA K etal.: Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res. (1996) 56:2945–2958.
   Google Scholar
• NERVI C, FERRARA FF, FANELLI M et al.: Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RAR fusion protein. Blood (1998) 92:2244–2251.
   PubMed Web of Science ®Google Scholar
• CHEN GQ, ZHU J, SHI XG et al.: In vitro studies oncellular and molecular mechanisms of arsenic trioxide (As203) in the treatment of acute promyelo-cytic leukemia: As203 induces NB4 cell apoptosis with downregulation of Bc1-2 expression and modulation of PML-RAR alpha/PML proteins. Blood (1996) 88:1052–1061.
   PubMed Web of Science ®Google Scholar
• SHEN Z-X, CHEN G-Q, NI J-H et al.: Use of arsenictrioxide (As203) in the treatment of acute promyelo-cytic leukemia (APL): II. Clinical efficacy and pharma-co kineti cs in relapsed patients. Blood (1997) 89:3354–3360.
   Google Scholar
• ZHU J, KOKEN MH, QUIGNON F et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Nati Acad. ScL USA (1997) 94:3978–3983.
   PubMed Web of Science ®Google Scholar
• SOIGNET SL, MASLAK P, WANG ZG et al.: Completeremission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl. J. Med. (1998) 339:1341–1348.
   PubMed Web of Science ®Google Scholar
• SHAO W, FANELLI M, FERRARA FF etal.: Arsenic trioxideas an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J. Nati Cancer Inst. (1998) 90:124–133.
   Google Scholar
• CHEN GQ, SHI XG, TANG W etal.: Use of arsenic trioxide(As203) in the treatment of acute promyelocytic leukemia (APL): I. As203 exerts dose-dependent dual effects on APL cells. Blood (1997) 89:3345–3353.
   Google Scholar
• CHOMIENNE C, BALLERINI P, BALITRAND N et al.:Retinoic acid therapy for promyelocytic leukaemia. Lancet (1989) 2:746–747.
   PubMed Web of Science ®Google Scholar
• NERVI C, GRIPPO JF, SHERMAN MI, GEORGE MD, JETTENAM: Identification and characterization of nuclear retinoic acid-binding activity in human myeloblastic leukemia HL-60 cells. Proc. Natl. Acad. ScL USA (1989) 86:5854–5458.
   PubMed Web of Science ®Google Scholar
• COLLINS SJ, ROBERTSON KA, MUELLER L: Retinoicacid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha). Mol. Cell Biol. (1990) 10:2154–2163.
   PubMed Web of Science ®Google Scholar
• GALLAGHER RE, SAID F, PUA I, PAPENHAUSEN PR, PAIETTA E, WIERNIK PH: Expression of retinoic acid receptor-alpha mRNA in human leukemia cells with variable responsiveness to retinoic acid. Leukemia (1989) 3:789–795.
   PubMed Web of Science ®Google Scholar
• KIZAKI M, IKEDA Y, TANOSAKI R et al.: Effects of novel retinoic acid compound, 9-cis-retinoic acid, on prolif-eration, differentiation, and expression of retinoic acid receptor-alpha and retinoid X receptor-alpha RNA by HL-60 cells. Blood (1993) 82:3592–3599.
   PubMed Web of Science ®Google Scholar
• ROBERTSON KA, EMAMI B, COLLINSSJ: Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood (1992) 80: 1885-1889.
   Google Scholar
• DERMIME S, GRIGNANI F, CLERICI M etal.: Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha protein. Blood (1993) 82:1573–1577.
   Google Scholar
• SHAO W, BENEDETTI L, LAMPH WW, NERVI C, MILLER WH JR: A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAlla mutation. Blood (1997) 89:4282–4289.
   PubMed Web of Science ®Google Scholar
• WARRELL RP JR, DE THE H, WANG ZY, DEGOS L: Acute promyelocytic leukemia. N. Engl. J. Med. (1993) 329:177–189.
   PubMed Web of Science ®Google Scholar
• DEGOS L, DOMBRET H, CHOMIENNE H et al: All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood (1995) 85: 2643–2653.
   PubMed Web of Science ®Google Scholar
• ••Although somewhat out of date, it contains a detailedpractical review on the principals of clinical usage of ATRA in APL.
   Google Scholar
• WARRELL RP JR, FRANKEL SR, MILLER WH JR et al.: Differ-entiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl. J. Med. (1991) 324:1385–1393.
   Google Scholar
• DEGOS L: Is acute promyelocytic leukemia a curable disease? Treatment strategy for a long-term survival. Leukemia (1994) 8:911–913.
   PubMed Web of Science ®Google Scholar
• MUINDI J, FRANKEL SR, MILLER WH JR et al: Continuous treatment with all-trans retinoic acid causes a progres-sive reduction in plasma drug concentrations: implications for relapse and retinoid 'resistance' in patients with acute promyelocytic leukemia. Blood (1992) 79:299.
   PubMed Web of Science ®Google Scholar
• FRANKEL SR, EARDLEY A, LAUWERS G, WEISS M, WARRELL RP JR: The 'retinoic acid syndrome' in acute promyelocytic leukemia. Ann. Int. Merl. (1992) 117:292–296.
   PubMed Web of Science ®Google Scholar
• DE BOTTON S, DOMBRET H, SANZ M et al.: Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed. Blood (1998) 92:2712–2718.
   PubMed Web of Science ®Google Scholar
• •A large study describing the ATRA syndrome in the European APL93 clinical trial and a good review of the litera-ture on this complication.
   Google Scholar
• TALLMAN MS, ANDERSEN JW, SCHIFFER CA et al.: All-trans-retinoic acid in acute promyelocytic leukemia. N Engl. J. Merl. (1997) 337:1021–1026.
   PubMed Web of Science ®Google Scholar
• •The results on the randomised U.S. intergroup APL trial.
   Google Scholar
• WILEY JS, FIRKIN FC: Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group. Leukemia (1995) 9:774–779.
   Google Scholar
• FENAUX P, LE DELEY MC, CASTAIGNE S et al.: Effect of all trans retinoic acid in newly diagnosed acute promye-locytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood (1993) 82:3241–3249.
   Google Scholar
• FENAUX P, CHASTANG C, CHEVRET S et al.: A random-ized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood (1999) 94:1192–1200.
   PubMed Web of Science ®Google Scholar
• •The results of the European APL93 clinical trial and review of the literature of treatment of this disease.
   Google Scholar
• ASOU N, ADACHI K, TAMURA J et al.: Analysis of prognostic factors in newly diagnosed acute promye-locytic leukemia treated with all-trans retinoic acid and chemotherapy. J. Clin. Oncol (1998) 16:78–85.
   PubMed Web of Science ®Google Scholar
• SOIGNET S, FLEISCHAUER A, POLYAK T, HELLER G, WARRELL RP JR: All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study. Cancer Chemother. Pharmacol (1997) 40(Suppl.):S25–29.
   Google Scholar
• FENAUX P, CASTAIGNE S, DOMBRET H et al.: All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood (1992) 80:2176–2181.
   PubMed Web of Science ®Google Scholar
• FENAUX P, WATTEL E, ARCHIMBAUD E et al.: Prolonged follow-up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia. The French APL Group [letter]. Blood (1994) 84:666–667.
   Google Scholar
• AVVISATI G, LO COCO F, DIVERIO D et al.: AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia. Blood (1996) 88: 1390–1398.
   PubMed Web of Science ®Google Scholar
• KANAMARU A, TAKEMOTO Y, TANIMOTO M et al.: All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood (1995) 85:1202–1206.
   PubMed Web of Science ®Google Scholar
• FRANKEL SR, EARDLEY A, HELLER G et al.: All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann. Intern. Med. (1994) 120:278–286.
   Google Scholar
• BURNETT AK, GOLDTSONE AH, GRAY RG, WHEATLEY K: All trans retinoic acid given concurently with induction chemothearpy improves outcome in APL: Results of the UK MRC ATRA trial. Blood (1997) (Suppl. 1):Abstract 1474.
   Google Scholar
• ESTEY E, THALL PF, PIERCE S, KANTARJIAN H, KEATING M: Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J. Clin. Oncol (1997) 15:483–490.
   PubMed Web of Science ®Google Scholar
• MARTY M, GANEM G, FISCHER J et al.: Boiron M. Acute promyelocytic leukemia: retrospective study of 119 patients treated with daunorubicin. Nouv. Rev. Fran. Hematol (1984) 26:371–378.
   Google Scholar
• KANTARJIAN HM, KEATING MJ, WALTERS RS, SMITH TL, MCCREDIE KB, FREIREICH EJ: Role of maintenance chemotherapy in acute promyelocytic leukemia. Cancer (1987) 59:1258–1263.
   PubMed Web of Science ®Google Scholar
• LO COCO F, DIVERIO D, AVVISATI G et al.: Therapy of molecular relapse in acute promyelocytic leukemia. Blood (1999) 94:2225–2229.
   PubMed Web of Science ®Google Scholar
• •Using the PCR to detect minimal residual disease in APL, to define the goal of treatment as PCR negativity for the fusion gene and how to treat patients who are PCR positive.
   Google Scholar
• DIVERIO D, ROSSI V, AVVISATI G et al.: Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIIVIEMA-AIEOP multicenter 'AIDA' trial. Blood (1998) 92:784–789.
   PubMed Web of Science ®Google Scholar
• ESTEY EH, GILES FJ, KANTARJIAN H et al.: Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood (1999) 94:2230–2235.
   PubMed Web of Science ®Google Scholar
• •A interesting paper using ATRA in an liposomal intravenous form without chemotherapy to induce a durable PCR remission.
   Google Scholar
• LO COCO F, DIVERIO D, PANDOLFI PP et al.: Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet (1992) 340:1437–1438.
   PubMed Web of Science ®Google Scholar
• MELONI G, DIVERIO D, VIGNETTI M et al.: Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR fusion gene. Blood (1997) 90:1321–1325.
   PubMed Web of Science ®Google Scholar
• CASTAIGNE S, CHOMIENNE C, DANIEL T et al.: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood (1990) 76:1704–1709.
   PubMed Web of Science ®Google Scholar
• DEGOS L, CHOMIENNE C, DANIEL MT et al.: Treatment of first relapse in acute promyelocytic leukemia with all-trans retinoic acid. Lancet (1990) 336:1440–1441.
   PubMed Web of Science ®Google Scholar
• CHEN A, XUE YQ, ZHANG R et al: A.clinical and experi-mental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood (1991) 78:1413–1419.
   Google Scholar
• MUINDI JRF, FRANKEL SR, HUSELTON C et al.: Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res. (1992) 52:2138–2146.
   PubMed Web of Science ®Google Scholar
• MUINDI J, YOUNG C: Lipid hydroperoxidase greatly increase the rate of oxidative catabolism of all-trans retinoic acid by human microsomes genetically enriched in specified cytochrome 450 isoforms. Cancer Res. (1993) 53:1226
   PubMed Web of Science ®Google Scholar
• WARRELL RJ JR: Retinoid resistance in acute promyelo-cytic leukemia: New mechanisms, strategies and implications. Blood (1993) 82:1949–1953.
   PubMed Web of Science ®Google Scholar
• DELVA L, CORNIC M, BALITRAND N et al.: Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood (1993) 82: 2175–2181.
   PubMed Web of Science ®Google Scholar
• MILLER WH, JAKUBOWSKI A, TONG WP et al.: 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. Blood (1995) 85:3021–3027.
   PubMed Web of Science ®Google Scholar
• DING W, LI YP, NOBILE LM et al.: Leukemic cellular retinoic acid resistance and missense mutations in the PML-RAR a fusion gene after relapse of acute promye-locytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood (1998) 92:1172–1183.
   PubMed Web of Science ®Google Scholar
• IMAIZUMI M, SUZUKI H, YOSHINARI M et al.: Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood (1998) 92:374–382.
   PubMed Web of Science ®Google Scholar
• CHAO N, HUA Y, TING Y et al.: Studies on treatment of acute promyelocytic leukemia with arsenic arioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood (1999) 94:3315–3324.
   PubMed Web of Science ®Google Scholar
• •A clinical trial of using arsenic trioxide that includes an updated review of this topic.
   Google Scholar
• SOIGNET S, FRANKEL S, TALLMAN M et al.: US multicenter trial of arsenic trioxide (at) in acute promyelocytic leukemia (APL). Blood (1999) 94 (Suppl. 1):689A.
   Google Scholar
• WANG Z-G, RIVI R, DELVA L et al.: Arsenic Trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RAR a independent manner. Blood (1998) 92:1497–1504.
   PubMed Web of Science ®Google Scholar
• GIANNI M, KOKEN MHM, CHELBI-ALIX MK et al.: Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood (1998) 91:4300–4310.
   PubMed Web of Science ®Google Scholar
• MEHTA K, SANDEGHI T, MCQUEEN T, LOPEZ-BERNSTEIN G: Liposome encapsulation circumvents the hepatic clearance mechanisms of all- trans-retinoic acid. Leukemia Res. (1994) 18:587–595.
   PubMed Web of Science ®Google Scholar
• ESTEY E, THALL PF, MEHTA K et al.: Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood (1996) 87:3650–3654.
   PubMed Web of Science ®Google Scholar
• DRACH J, LOPEZ-BERESTEIN G, MCQUEEN T, ANDREEFF M, MEHTA K: Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid. Cancer Res. (1993) 53:2100.
   PubMed Web of Science ®Google Scholar
• ESTEY E, DOUER D, WIERNICK P, REED P, THOMPSON J, GORDON D: Treatment of recurrecnt acute promyelo-cytic leukemia with liposomal all trans retinoic acid. Blood (1997) (Supp1.1):332a.
   Google Scholar
• TOBITA T, TAKESHITA A, KITAMURA K et al.: Treatment with a new synthetic Retinoid, Am80, of acute promye-locytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood (1997) 90:967–973
   PubMed Web of Science ®Google Scholar